In mouse models, administration of purified P9 protein improved glucose homeostasis and reduced metabolic disease markers
Yet it is Lillys newest drug, tirzepatide, which poses a more serious threat to Novos market dominance
Cell Metab
The manufacturer, Eli Lilly Co., has submitted orforglipron to the FDA for approval for use in weight management, with a decision expected in the second quarter of 2026
Back US FDA (4 Nov 2021) 'FDA approves new drug treatment for chronic weight management, first since 2014''
The additional receptors allow retatrutide to influence appetite, blood sugar, and fat metabolism through multiple pathways simultaneously, which is believed to account for the difference in efficacy